Co-expression of IL-10 receptor as a strategy to enhance the effects of a DNA vaccine focused on the control of tumors induced by HPV-16

• Grant number: 14/11073-1
• Support Opportunities: Scholarships in Brazil - Master
• Start date: August 01, 2014
• End date: July 31, 2016
• Field of knowledge: Biological Sciences - Microbiology
• Agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Luis Carlos de Souza Ferreira
• Grantee: Jamile Ramos da Silva
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

The Laboratory for Vaccine Development (LDV) of USP created a therapeutic vaccine strategy for cervical cancer that employs a vector encoding the E7 protein of HPV-16 fused to glycoprotein D (gD) of herpes simplex virus type 1 (HSV -1). The pgDE7h DNA vaccine showed preventive and therapeutic properties in mice when they are challenged with TC-1 cells which express E6 and E7 oncoproteins of HPV-16. The goal of this project is evaluate the effects of administration of a plasmid encoding the soluble receptor of IL-10 (pIL10R) in improve of DNA vaccine pgDE7h in the control of tumors induced by HPV-16. This proposal seeks to reduce the immunosuppression mediated by IL-10 in tumor immune evasion. To do so will be testing different vaccine regimens. Initially, we will evaluate the therapeutic potential of tumor regression in the combined vaccine varying the time interval between the animal challenge with TC-1 cells and the administration of the vaccine. Afterwards, the dose of the vaccine will be gradually reduced in the pursuit of its minimum amount capable of inducing therapeutic protection. The response of E7-specific T lymphocytes triggered by the vaccine will be determined by different experimental approaches. Furthermore, the effect of the vaccine will be assessed by the expansion of immunosuppressive cells as regulatory T cells and myeloid suppressor cells as well as the cytokine profile. Subsequent, the role of IL-10 in mice deficient for the gene will be found after the administration of the vaccine pdDE7h. The results obtained during the execution of this project will contribute to the development of a novel vaccine strategy that can act both in inducing an anti-tumor response as the control of immunosuppression. (AU)

Scientific publications

(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)

SILVA, JAMILE R.; SALES, NATIELY S.; SILVA, MARIANGELA O.; APS, LUANA R. M. M.; MORENO, ANA C. R.; RODRIGUES, ELAINE G.; FERREIRA, LUIS C. S.; DINIZ, MARIANA O.. Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model. CANCER IMMUNOLOGY IMMUNOTHERAPY, v. 68, n. 5, p. 753-763, MAY 2019. (16/00708-1, 16/14344-1, 15/16505-0, 16/11397-7, 13/15360-2, 11/51218-0, 14/11073-1)

RAMOS DA SILVA, JAMILE; RAMOS MORENO, ANA CAROLINA; SILVA SALES, NATIELY; DE OLIVEIRA SILVA, MARIANGELA; APS, LUANA R. M. M.; PORCHIA, BRUNA F. M. M.; BITENCOURT RODRIGUES, KARINE; CESTARI MORENO, NATALIA; VENCESLAU-CARVALHO, ALEXIA ADRIANNE; MENCK, CARLOS FREDERICO M.; et al. A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model. ONCOIMMUNOLOGY, v. 10, n. 1, JAN 1 2021. (11/51218-0, 16/14344-1, 16/00708-1, 15/16505-0, 18/26555-2, 16/11397-7, 17/21358-1, 16/11594-7, 14/11073-1)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

SILVA, Jamile Ramos da. Control of immunosuppression as strategy to enhance the effects of a DNA vaccine against tumors induced by HPV-16.. 2016. Master's Dissertation - Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB/SDI) São Paulo.